147 related articles for article (PubMed ID: 37391438)
1. Nrh L11R single nucleotide polymorphism, a new prediction biomarker in breast cancer, impacts endoplasmic reticulum-dependent Ca
Duong MQ; Gadet R; Treilleux I; Borel S; Nougarède A; Marcillat O; Gonzalo P; Mikaelian I; Popgeorgiev N; Rimokh R; Gillet G
Cell Death Dis; 2023 Jul; 14(6):392. PubMed ID: 37391438
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10.
Nougarede A; Popgeorgiev N; Kassem L; Omarjee S; Borel S; Mikaelian I; Lopez J; Gadet R; Marcillat O; Treilleux I; Villoutreix BO; Rimokh R; Gillet G
Cancer Res; 2018 Mar; 78(6):1404-1417. PubMed ID: 29330143
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
Turiján-Espinoza E; Ruíz-Rodríguez VM; Uresti-Rivera EE; Martínez-Leija E; Zermeño-Nava JJ; Guel-Pañola A; Romano-Moreno S; Vargas-Morales JM; Portales-Pérez DP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):843-853. PubMed ID: 33740100
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting.
Lu J; Wu Z; Peng J; Xu S; Zhou L; Lin Y; Wang Y; Yin W; Lu J
Int J Biol Markers; 2020 Sep; 35(3):90-101. PubMed ID: 33073683
[TBL] [Abstract][Full Text] [Related]
6. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
7. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Kim HJ; Im SA; Keam B; Ham HS; Lee KH; Kim TY; Kim YJ; Oh DY; Kim JH; Han W; Jang IJ; Kim TY; Park IA; Noh DY
Cancer Sci; 2015 Jan; 106(1):86-93. PubMed ID: 25410489
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers.
Barrón-Gallardo CA; Garcia-Chagollán M; Morán-Mendoza AJ; Delgadillo-Cristerna R; Martínez-Silva MG; Aguilar-Lemarroy A; Jave-Suárez LF
Technol Cancer Res Treat; 2022; 21():15330338211068965. PubMed ID: 34981997
[TBL] [Abstract][Full Text] [Related]
9. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
10. Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK).
Zhou H; Zhang Y; Fu Y; Chan L; Lee AS
J Biol Chem; 2011 Jul; 286(29):25687-96. PubMed ID: 21622563
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Charehbili A; van Laarhoven HW; Mooyaart AL; Dekker-Ensink NG; van de Ven S; Janssen LG; Swen JJ; Smit VT; Heijns JB; Kessels LW; van der Straaten T; Böhringer S; Gelderblom H; van der Hoeven JJ; Guchelaar HJ; Pijl H; Kroep JR;
Breast Cancer Res; 2016 Jan; 18(1):3. PubMed ID: 26738606
[TBL] [Abstract][Full Text] [Related]
12. OCA2 rs4778137 polymorphism predicts survival of breast cancer patients receiving neoadjuvant chemotherapy.
Li XP; Lan JY; Liu DQ; Zhou H; Qian MM; Wang WW; Yang M
Gene; 2018 Apr; 651():161-165. PubMed ID: 29409738
[TBL] [Abstract][Full Text] [Related]
13. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
[TBL] [Abstract][Full Text] [Related]
15. Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial.
Le Morvan V; Litière S; Laroche-Clary A; Ait-Ouferoukh S; Bellott R; Messina C; Cameron D; Bonnefoi H; Robert J
Pharmacogenomics J; 2015 Feb; 15(1):63-8. PubMed ID: 24958282
[TBL] [Abstract][Full Text] [Related]
16. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
Bownes RJ; Turnbull AK; Martinez-Perez C; Cameron DA; Sims AH; Oikonomidou O
Breast Cancer Res; 2019 Jun; 21(1):73. PubMed ID: 31200764
[TBL] [Abstract][Full Text] [Related]
17. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.
George J; Dharanipragada K; Krishnamachari S; Chandrasekaran A; Sam SS; Sunder E
Clin Breast Cancer; 2009 Aug; 9(3):161-5. PubMed ID: 19661039
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
Hein A; Lambrechts D; von Minckwitz G; Häberle L; Eidtmann H; Tesch H; Untch M; Hilfrich J; Schem C; Rezai M; Gerber B; Dan Costa S; Blohmer JU; Schwedler K; Kittel K; Fehm T; Kunz G; Beckmann MW; Ekici AB; Hanusch C; Huober J; Liedtke C; Mau C; Moisse M; Müller V; Nekljudova V; Peuteman G; Rack B; Rübner M; Van Brussel T; Wang L; Weinshilboum RM; Loibl S; Fasching PA
Int J Cancer; 2015 Dec; 137(12):2981-8. PubMed ID: 26100253
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility.
Zhang N; Li X; Tao K; Jiang L; Ma T; Yan S; Yuan C; Moran MS; Liang F; Haffty BG; Yang Q
BMC Med Genet; 2011 Apr; 12():48. PubMed ID: 21457555
[TBL] [Abstract][Full Text] [Related]
20. A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Wu L; Yao L; Zhang H; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Yin CC; Xie Y
Oncotarget; 2016 Jan; 7(4):5042-52. PubMed ID: 26573232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
